These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 17306187)

  • 1. [Constrained competition in parallel drug importation: the case of simvastatin in Germany, the Netherlands, and the United Kingdom].
    Costa-Font J; Kanavos P
    Gac Sanit; 2007; 21(1):53-9. PubMed ID: 17306187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The economics of parallel trade.
    Danzon PM
    Pharmacoeconomics; 1998 Mar; 13(3):293-304. PubMed ID: 10178655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Competitive pricing within pharmaceutical classes: evidence on "follow-on" drugs in Germany 1993-2008.
    Mueller MT; Frenzel A
    Eur J Health Econ; 2015 Jan; 16(1):73-82. PubMed ID: 24370790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does reimportation reduce price differences for prescription drugs? Lessons from the European Union.
    Kyle MK; Allsbrook JS; Schulman KA
    Health Serv Res; 2008 Aug; 43(4):1308-24. PubMed ID: 18355258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parallel imports and a mandatory substitution reform: a kick or a muff for price competition in pharmaceuticals?
    Granlund D; Koksal-Ayhan MY
    Eur J Health Econ; 2015 Dec; 16(9):969-83. PubMed ID: 25404013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Price comparison of high-cost originator medicines in European countries.
    Vogler S; Zimmermann N; Babar ZU
    Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):221-230. PubMed ID: 27658050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of Medicine Prices in New Zealand and 16 European Countries.
    Vogler S; Kilpatrick K; Babar ZU
    Value Health; 2015 Jun; 18(4):484-92. PubMed ID: 26091603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study.
    Vogler S; Vitry A; Babar ZU
    Lancet Oncol; 2016 Jan; 17(1):39-47. PubMed ID: 26670089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. International trade and determinants of price differentials of insulin medicine.
    Helble M; Aizawa T
    Health Policy Plan; 2017 Feb; 32(1):1-10. PubMed ID: 27346189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The 1996 pricing and reimbursement policy in The Netherlands.
    de Vos CM
    Pharmacoeconomics; 1996; 10 Suppl 2():75-80. PubMed ID: 10163439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is medicines parallel trade 'regulatory arbitrage'?
    Costa-Font J
    Int J Health Econ Manag; 2016 Dec; 16(4):321-336. PubMed ID: 27878693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implication of external price referencing and parallel trade on pharmaceutical expenditure: indirect evidence from lower-income European countries.
    Elek P; Takács E; Merész G; Kaló Z
    Health Policy Plan; 2017 Apr; 32(3):349-358. PubMed ID: 27697777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Why drug prices will go lower.
    Tully S
    Fortune; 1993 May; 127(9):56-8, 60, 62 passim. PubMed ID: 10125261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Has the European union achieved a single pharmaceutical market?
    Timur A; Picone G; DeSimone J
    Int J Health Care Finance Econ; 2011 Dec; 11(4):223-44. PubMed ID: 21984119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biosimilar versus patented erythropoietins: learning from 5 years of European and Japanese experience.
    Bocquet F; Paubel P; Fusier I; Cordonnier AL; Sinègre M; Le Pen C
    Appl Health Econ Health Policy; 2015 Feb; 13(1):47-59. PubMed ID: 25189295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Policies encouraging price competition in the generic drug market: Lessons from the European experience].
    Puig-Junoy J
    Gac Sanit; 2010; 24(3):193-9. PubMed ID: 20189690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Behind-the-counter statins: a silver bullet for reducing costs and increasing access?
    Sood N; Sun E; Zhuo X
    Health Serv Res; 2012 Feb; 47(1 Pt 1):174-87. PubMed ID: 22091792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct and indirect savings from parallel imports in Sweden.
    Granlund D
    Health Econ Rev; 2022 Aug; 12(1):46. PubMed ID: 36044111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parallel imports of pharmaceuticals in the European Union.
    Darbà J; Rovira J
    Pharmacoeconomics; 1998; 14 Suppl 1():129-36. PubMed ID: 10186474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parallel imports and the pricing of pharmaceutical products: evidence from the European Union.
    Ganslandt M; Maskus KE
    J Health Econ; 2004 Sep; 23(5):1035-57. PubMed ID: 15353192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.